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The current state-of-the-art for the production of glycoconjugate vaccines is a lengthy and complex series of
process steps. An exciting alternative is Protein Glycan Coupling Technology (PGCT), where glycoconjugates
are produced in vivo 1,2. This offers a significant reduction in the time and cost burden of glycoconjugate
production, making this technology much more feasible for providing vaccines in developing countries. Current
research seeks to apply this technology for pneumococcal vaccines 2, however much process optimisation must
be done before this is achievable. This work seeks to provide an automated screening platform at the
microscale, enabling the rapid screening of different process variables at considerably smaller volumes.
Scaling was performed based upon
oxygen mass transfer3,4, whereby
engineering correlations were used to
estimate the value for kLa in both
falcon tubes (bench scale production)
and microwells (scale down
platform). This provided a good
match in cell culture performance and
enabled the development of a
microscale platform amenable to
automation.
Using a combination of feedback
loops and executable commands, the
automated platform developed
Figure 1 – The scale down from falcon tube culture (top) to
showed robust and consistent
microwells (bottom).
performance in both cell growth and
product expression, with fully hands-free operation. The automated platform was then successfully used for a
number of screening studies, identifying the best producing engineered E.coli strain for the glycoconjugate
vaccine, an efficient induction protocol and the best carrier protein constructs 5.
Experimentally determined kLa values were then used to scale up the microscale platform to a bench-scale
bioreactor culture. This proved the relevance of the data gathered at the microscale to bioreactor cultures and
demonstrated the successful transition from shaken to stirred agitation with identical product expression.
This work sought to develop an automated screening tool for ongoing glycoconjugate vaccine development.
Thus far, the automated platform has been used in a number of screening studies and has proven scalability
with a bench-scale bioreactor culture process. Continued work seeks to optimise a defined media protocol with
more rigorous downstream processing to progress this vaccine candidate toward Clinical Phase I trials.
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